Blueprint Medicines Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPMC research report →
Companywww.blueprintmedicines.com
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
- CEO
- Kathryn Haviland
- IPO
- 2015
- Employees
- 682
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $8.36B
- P/E
- -166.47
- P/S
- 28.27
- P/B
- 24.07
- EV/EBITDA
- -122.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.53%
- Op Margin
- -27.82%
- Net Margin
- -16.72%
- ROE
- -15.44%
- ROIC
- -8.21%
Growth & Income
- Revenue
- $508.82M · 104.04%
- Net Income
- $-67,089,000 · 86.77%
- EPS
- $-1.07 · 87.22%
- Op Income
- $-212,044,000
- FCF YoY
- 56.46%
Performance & Tape
- 52W High
- $129.55
- 52W Low
- $73.04
- 50D MA
- $116.52
- 200D MA
- $98.82
- Beta
- 0.83
- Avg Volume
- 3.29M
Get TickerSpark's AI analysis on BPMC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 25 | Landsittel Michael | other | 21,353 |
| Jul 17, 25 | Landsittel Michael | sell | 51,102 |
| Jul 17, 25 | Landsittel Michael | sell | 25,000 |
| Jul 17, 25 | Landsittel Michael | sell | 25,000 |
| Jul 17, 25 | Landsittel Michael | sell | 10,000 |
| Jul 17, 25 | Landsittel Michael | other | 43,175 |
| Jul 17, 25 | Landsittel Michael | sell | 19,500 |
| Jul 17, 25 | Landsittel Michael | sell | 25,000 |
| Jul 17, 25 | Landsittel Michael | sell | 25,000 |
| Jul 17, 25 | Landsittel Michael | sell | 22,000 |
Our BPMC Coverage
We haven't published any research on BPMC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BPMC Report →